盘中深跌4%后又回拉！港股通创新药ETF（520880）连日回落之际，巨额资金反向加仓

Group 1 - The Hong Kong innovative drug sector is experiencing a significant pullback, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index dropping nearly 4% and most constituent stocks declining [1] - Major stocks such as Kelun-Botai Biopharmaceutical, CanSino Biologics, and Zai Lab fell over 5%, while China Biologic Products and 3SBio dropped over 4% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a price drop of over 4% but later reduced its decline, indicating positive buying sentiment with a real-time premium rate exceeding 0.4% [1] Group 2 - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has risen 101.58% year-to-date as of July 31, significantly outperforming the Hang Seng Index and Hang Seng Technology Index by 78.08 and 79.53 percentage points, respectively [2] - The ETF is the first in the market to track this index, focusing on the innovative drug industry chain with a high concentration of leading companies [2]